Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (95405)	11/2/2001 4:08:17 PM
From: Jim Bishop	Read Replies (3) \| Respond to of 150070

TDOT UNBEAL!

To: SSP who wrote (95405)	11/2/2001 4:19:33 PM
From: vds4	Respond to of 150070

nice finish for the week for SINA by the way. heck, nice steady month of october. martin

To: SSP who wrote (95405)	11/3/2001 1:23:59 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

ESPR LIST suggestion. Based on clinical trial results I'd use impact date of end Q1 2002 to be safe, I'm actually more interested in LUV (ETC -588) working, and I'll be first in line at my cardiologist, and to heck with the share price....it works, that will follow. From Sept 6 news: "Within the next 12 months, all of our product candidates will be in various stages of clinical development." biz.yahoo.com From Oct 9 news: "....today announced it has received regulatory approval to initiate a Phase I clinical study of its RLT Peptide product candidate (ETC-642) in patients with existing cardiovascular disease. This program will commence in November 2001. The Phase I clinical trial will be a single-dose study in patients with stable atherosclerosis to determine the safety, tolerability, pharmacokinetics and lipid effects of ETC-642. The trial will be conducted by Mayo Clinic and managed by Mayo Physician Alliance for Clinical Trials, a Mayo-led organization focusing on advancing patient care through well-designed multi-center clinical trials. Mehmood A. Khan, MD, a Mayo Clinic endocrinologist, will serve as the principal investigator of the study." biz.yahoo.com From Nov 1 coverage report: "Vancouver, Nov 01, 2001 (smallcapcenter.com via COMTEX) -- A promising new way to clean away fatty gunk from the hearts and arteries of millions of patients has lead to one analyst's new appreciation of 'good' cholesterol and his belief that Esperion Therapeutics Inc. (NASDAQ: ESPR) could shoulder its way into a multi-billion dollar market. Enter Esperion's lead contender: LUV (ETC-588). Developed by Esperion, LUV or Large Unilamellar Vesicles are spherical particles fashioned from HDL. Injected into a patient, it acts like a horde of tiny cleaners, removing the sticky cholesterol for cells and arterial walls alike. Tireless cleaners. According to Esperion, LUV can cycle back through the arteries "several times" to remove more heart-stopping gunk and thus, it's hoped, markedly improve cardiovascular health and function. If it does work, it will be the first of a new family of drugs and the only one specifically focused on turbo-powering HDL. A Phase II clinical trial is now in progress. Designed to evaluate multiple-dose safety, tolerability and frequency of treatment in patients with known atherosclerosis, Monane says the results - good or bad - are set to land by the end of Q4 of this year. "So, that's sooner rather than later. "Some people say it's early and it is early. But the data so far has been very positive and that makes me think more likely than not that the Phase II trials are going to be positive as well." ABOUT ESPERION: Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called ``HDL Therapy,'' which is based on the Company's understanding of high-density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arteries and other tissues and for their transport to the liver for elimination from the body. The goal of Esperion is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has five product candidates under development for the treatment of cardiovascular and metabolic diseases. Esperion is listed on the Nasdaq National Market under the symbol ``ESPR.''